Nausea and vomiting associated with chemotherapy remains an area of unmet need for patients, despite substantial advancements in antiemetic research in the past 10 years. One such advancement is the use of olanzapine as an antiemetic drug. Olanzapine has been shown to significantly improve chemotherapy-induced nausea and vomiting when added to a standard triple combination of antiemetics, supported by evidence from Navari and colleagues' trials, ^,  but is currently a contentious issue, as the initial trials investigating 10 mg olanzapine showed it was associated with side-effects. Olanzapine added to triple combination therapy is already recommended by the American Society of Clinical Oncology and National Comprehensive Cancer Network antiemetic guidelines, ^,  whereas the Multinational Association of Supportive Care in Cancer and the European Society of Medical Oncology guidelines have made more cautious recommendations, all based on a 10 mg dose.

中文翻译：

---

是时候重新考虑奥氮平的剂量了。

尽管在过去的十年中止吐研究取得了重大进展，但与化疗相关的恶心和呕吐仍然是患者未满足的需求领域。一种这样的进步是奥氮平作为止吐药的用途。在Navari等人的试验证据支持下，将奥氮平添加到标准的三联止吐药中后，可显着改善化疗引起的恶心和呕吐^， 但目前是一个有争议的问题，因为调查10毫克奥氮平的初步试验显示它与副作用有关。美国临床肿瘤学会和国家综合癌症网络止吐指南已建议在三联疗法中加入奥氮平^，  而多国癌症支持治疗协会和欧洲肿瘤医学学会指南则提出了更为谨慎的建议，所有建议均基于10毫克剂量。